Market Cap 520.04M
Revenue (ttm) 262.60M
Net Income (ttm) -80.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -30.77%
Debt to Equity Ratio 0.00
Volume 3,032,500
Avg Vol 770,676
Day's Range N/A - N/A
Shares Out 64.52M
Stochastic %K 63%
Beta 1.71
Analysts Sell
Price Target $14.80

Company Profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein fo...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 535 1456
Address:
5 Science Park, 395 Winchester Avenue, New Haven, United States
TwinTurboBul161
TwinTurboBul161 Aug. 4 at 7:44 PM
$OMEX $ARVN <>gems
0 · Reply
biopuzzle
biopuzzle Aug. 4 at 2:35 PM
$ARVN @outlawinvestor1 GM, hope you are doing well. I missed part of CC today. Did they explain why Noah left? Thank you
1 · Reply
BullDonald
BullDonald Aug. 4 at 1:42 PM
$ARVN Biggest Positives 1. ARV-393 enrollment is finally accelerating 2. They're already talking about pivotal opportunities 3. SBMA program is progressing exactly as planned 4. Cash runway 5. Capital allocation Some hickups but Not Negative ARV-102 delayed due to regulatory process but Positive as they are in discusion with FDA, Europe and in Japan BCL6 data expectations is lowered intentionally by the management because of lower doses. Higly WELL MANAGED company VIBE that Big investors LOVE.
0 · Reply
EarningsInsider
EarningsInsider Aug. 4 at 1:17 PM
https://www.marketbeat.com/earnings/reports/2026-8-4-arvinas-inc-stock/ $ARVN Arvinas Earnings Transcript
0 · Reply
lex007
lex007 Aug. 4 at 12:41 PM
$ARVN interesting news and long term gem
0 · Reply
NewGuyHere94
NewGuyHere94 Aug. 4 at 11:39 AM
0 · Reply
Biotech80
Biotech80 Aug. 4 at 11:15 AM
$ARVN 💎💎💎💎💎💎
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 4 at 11:08 AM
$ARVN Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $2.61 up 410.71% YoY • Reported revenue of $249.7M up 1014.73% YoY • Arvinas believes its cash, cash equivalents, and marketable securities of $567.9 million as of June 30, 2026, is sufficient to fund planned operating expenses and capital expenditure requirements into 2028.
0 · Reply
NewGuyHere94
NewGuyHere94 Jul. 31 at 12:38 PM
$ARVN earnings next week, hopefully some data release. Still very optimistic
0 · Reply
diegosan21
diegosan21 Jul. 30 at 1:00 PM
$ARVN what's the news here?
1 · Reply
Latest News on ARVN
Arvinas reports Q2 EPS $2.58, consensus (28c)

2026-08-04T12:06:34.000Z - 14 hours ago

Arvinas reports Q2 EPS $2.58, consensus (28c)


Arvinas Earnings Call Transcript: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 14 hours ago

Arvinas Earnings Call Transcript: Q2 2026


Arvinas Earnings release: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 14 hours ago

Arvinas Earnings release: Q2 2026


Arvinas Quarterly report: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 14 hours ago

Arvinas Quarterly report: Q2 2026


Arvinas Transcript: AGM 2026

Jun 24, 2026, 8:00 AM EDT - 5 weeks ago

Arvinas Transcript: AGM 2026


Arvinas Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 9:55 AM EDT - 2 months ago

Arvinas Transcript: Jefferies Global Healthcare Conference 2026


Arvinas to Present at Jefferies Global Healthcare Conference

May 29, 2026, 4:01 PM EDT - 2 months ago

Arvinas to Present at Jefferies Global Healthcare Conference


Arvinas Employees Give Back During Company-wide Impact Day

May 18, 2026, 10:30 AM EDT - 2 months ago

Arvinas Employees Give Back During Company-wide Impact Day


Arvinas price target raised to $16 from $14 at BofA

2026-05-13T19:22:15.000Z - 2 months ago

Arvinas price target raised to $16 from $14 at BofA

PFE RIGL


Arvinas price target raised to $18 from $16 at BTIG

2026-05-13T12:47:37.000Z - 2 months ago

Arvinas price target raised to $18 from $16 at BTIG

RIGL


Arvinas price target raised to $20 from $18 at Barclays

2026-05-13T09:00:59.000Z - 2 months ago

Arvinas price target raised to $20 from $18 at Barclays


Arvinas Earnings Call Transcript: Q1 2026

May 12, 2026, 8:00 AM EDT - 3 months ago

Arvinas Earnings Call Transcript: Q1 2026


Arvinas Quarterly report: Q1 2026

May 12, 2026, 8:00 AM EDT - 3 months ago

Arvinas Quarterly report: Q1 2026


Arvinas Earnings release: Q1 2026

May 12, 2026, 8:00 AM EDT - 3 months ago

Arvinas Earnings release: Q1 2026


Arvinas reports Q1 EPS (90c), consensus (63c)

2026-05-12T11:49:11.000Z - 3 months ago

Arvinas reports Q1 EPS (90c), consensus (63c)


Arvinas management to meet with BTIG

2026-05-04T19:30:43.000Z - 3 months ago

Arvinas management to meet with BTIG


Arvinas price target raised to $24 from $21 at Citi

2026-05-04T09:10:10.000Z - 3 months ago

Arvinas price target raised to $24 from $21 at Citi


Arvinas gets early approval for Vepdeg, says Truist

2026-05-01T17:15:17.000Z - 3 months ago

Arvinas gets early approval for Vepdeg, says Truist


Arvinas trading resumes

2026-05-01T17:05:16.000Z - 3 months ago

Arvinas trading resumes


US FDA approves Pfizer, Arvinas' breast cancer drug

May 1, 2026, 12:37 PM EDT - 3 months ago

US FDA approves Pfizer, Arvinas' breast cancer drug

PFE


Arvinas trading halted, news pending

2026-05-01T15:27:03.000Z - 3 months ago

Arvinas trading halted, news pending


Arvinas Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Arvinas Proxy statement: Proxy filing


Arvinas Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Arvinas Proxy statement: Proxy filing


Arvinas price target raised to $21 from $18 at Citi

2026-03-19T10:11:49.000Z - 4 months ago

Arvinas price target raised to $21 from $18 at Citi


Arvinas Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 4:20 PM EDT - 5 months ago

Arvinas Transcript: Leerink Global Healthcare Conference 2026


Arvinas Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 1:10 PM EST - 5 months ago

Arvinas Transcript: TD Cowen 46th Annual Health Care Conference


Arvinas Earnings Call Transcript: Q4 2025

Feb 24, 2026, 8:00 AM EST - 5 months ago

Arvinas Earnings Call Transcript: Q4 2025


Arvinas Annual report: Q4 2025

Feb 24, 2026, 8:00 AM EST - 5 months ago

Arvinas Annual report: Q4 2025


Arvinas Earnings release: Q4 2025

Feb 24, 2026, 8:00 AM EST - 5 months ago

Arvinas Earnings release: Q4 2025


Arvinas to Participate in Upcoming Investor Conferences

Feb 23, 2026, 7:00 AM EST - 5 months ago

Arvinas to Participate in Upcoming Investor Conferences


Arvinas Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 3:30 AM EST - 9 months ago

Arvinas Transcript: Jefferies London Healthcare Conference 2025


Arvinas Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:00 AM EST - 9 months ago

Arvinas Earnings Call Transcript: Q3 2025


Arvinas Quarterly report: Q3 2025

Nov 5, 2025, 8:00 AM EST - 9 months ago

Arvinas Quarterly report: Q3 2025


Arvinas Earnings release: Q3 2025

Nov 5, 2025, 8:00 AM EST - 9 months ago

Arvinas Earnings release: Q3 2025


Arvinas Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Arvinas Earnings Call Transcript: Q2 2025


Arvinas Quarterly report: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Arvinas Quarterly report: Q2 2025


Arvinas Earnings release: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Arvinas Earnings release: Q2 2025


Arvinas Transcript: Study Update

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Arvinas Transcript: Study Update


Arvinas Press release: Study Update

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Arvinas Press release: Study Update


Arvinas Slides: Study Update

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Arvinas Slides: Study Update


TwinTurboBul161
TwinTurboBul161 Aug. 4 at 7:44 PM
$OMEX $ARVN <>gems
0 · Reply
biopuzzle
biopuzzle Aug. 4 at 2:35 PM
$ARVN @outlawinvestor1 GM, hope you are doing well. I missed part of CC today. Did they explain why Noah left? Thank you
1 · Reply
BullDonald
BullDonald Aug. 4 at 1:42 PM
$ARVN Biggest Positives 1. ARV-393 enrollment is finally accelerating 2. They're already talking about pivotal opportunities 3. SBMA program is progressing exactly as planned 4. Cash runway 5. Capital allocation Some hickups but Not Negative ARV-102 delayed due to regulatory process but Positive as they are in discusion with FDA, Europe and in Japan BCL6 data expectations is lowered intentionally by the management because of lower doses. Higly WELL MANAGED company VIBE that Big investors LOVE.
0 · Reply
EarningsInsider
EarningsInsider Aug. 4 at 1:17 PM
https://www.marketbeat.com/earnings/reports/2026-8-4-arvinas-inc-stock/ $ARVN Arvinas Earnings Transcript
0 · Reply
lex007
lex007 Aug. 4 at 12:41 PM
$ARVN interesting news and long term gem
0 · Reply
NewGuyHere94
NewGuyHere94 Aug. 4 at 11:39 AM
0 · Reply
Biotech80
Biotech80 Aug. 4 at 11:15 AM
$ARVN 💎💎💎💎💎💎
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 4 at 11:08 AM
$ARVN Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $2.61 up 410.71% YoY • Reported revenue of $249.7M up 1014.73% YoY • Arvinas believes its cash, cash equivalents, and marketable securities of $567.9 million as of June 30, 2026, is sufficient to fund planned operating expenses and capital expenditure requirements into 2028.
0 · Reply
NewGuyHere94
NewGuyHere94 Jul. 31 at 12:38 PM
$ARVN earnings next week, hopefully some data release. Still very optimistic
0 · Reply
diegosan21
diegosan21 Jul. 30 at 1:00 PM
$ARVN what's the news here?
1 · Reply
DarkH0rse91
DarkH0rse91 Jul. 22 at 7:21 PM
$SLS the delay is not the bull signal it is sold as. We’ve seen it before in other trials like $ARVN for example, it’s not a clear signal just like recruiting staff prior to the topline. All noise. Alpha was spent at the 60 event interim against a boundary near 0.51 and nothing crossed. That rules out a knockout effect. Slow accrual since is equally consistent with the control arm living long, which is the outcome that sinks the trial. I will say this though interim boundaries are conservative, so a genuine winning effect could still clear at 80. We don’t know what the BAT composition is. Having said that there remains a high probability of failure and it won’t be long till it all comes crumbling down for $SLS
0 · Reply
BullDonald
BullDonald Jul. 22 at 4:20 PM
$ARVN she is waking up.... 2 digits soon. Possible. release the Data
0 · Reply
Jtlo
Jtlo Jul. 17 at 12:10 PM
$ARVN premarket is very strange here
0 · Reply
NewGuyHere94
NewGuyHere94 Jul. 15 at 11:42 AM
$ARVN think we’ll essentially be sitting in the $8’s until the next set of trial results come to light, been in this for awhile but still think much to grow on here!
1 · Reply
BullDonald
BullDonald Jul. 14 at 11:54 PM
0 · Reply
Jtlo
Jtlo Jul. 10 at 5:35 PM
$ARVN Bottom line: ARVN spent roughly $92 million buying about 10 million shares at $9.09, and the latest reported numbers show they were still holding all of them.
1 · Reply
Jtlo
Jtlo Jul. 9 at 4:52 PM
$ARVN @Night_Owl_Biotech whats your thesis here
1 · Reply
BullDonald
BullDonald Jul. 9 at 3:39 PM
0 · Reply
Jtlo
Jtlo Jul. 9 at 3:29 PM
$ARVN in this with a large bag. Please be merciful on us. Let’s get back in the teens
0 · Reply
BioSpecialOne
BioSpecialOne Jul. 9 at 3:29 PM
$ARVN will this POS recover some day?
0 · Reply
BullDonald
BullDonald Jul. 8 at 2:24 PM
$ARVN any new on the Data relese ? Earning call is in August
0 · Reply
Jtlo
Jtlo Jul. 7 at 3:06 PM
$ARVN back in for more torture
0 · Reply